Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Analyst Ratings
Moderate Buy
6 Buy
11 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BMY Stock 12 Month Forecast
Average Price Target
$52.67
▲(13.88% Upside)
| Highest Price Target$68.00 | Average Price Target$52.67 | Lowest Price Target$36.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Hold
―
Reiterated
11/22/25
Truist Financial
―
Buy
―
Reiterated
11/20/25
Scotiabank
$45
Hold
-2.70%
Downside
Reiterated
11/20/25
BMO Capital
$47
Hold
1.62%
Upside
Reiterated
11/18/25
Citi
$48→$45
Hold
-2.70%
Downside
Reiterated
11/17/25
Piper Sandler
$62
Buy
34.05%
Upside
Reiterated
11/17/25
Morgan Stanley
$36
Sell
-22.16%
Downside
Reiterated
11/14/25
Bristol-Myers Squibb Faces Setbacks with Milvexian Trials, Justifying Sell RatingWe view this as another setback for the Factor XI thesis following the announcement in Nov. '23 that Bayer (covered by Thibault Boutherin) stopped the Ph3 OCEANIC-AF trial of asundexian (Factor XI) vs. Eliquis in afib early due to lack of efficacy; LINK. We previously highlighted that we viewed this news as an incremental negative for Milvexian as it could be reflective of the high bar set by Eliquis in afib and imply a lower probability of success for Milvexian in afib (LINK, LINK). As a reminder, BMY previously announced it was conducting clinical trial site reviews across all of its ongoing clinical trials in light of recent trial failures (Camzyos ODYSSEY-HCM, Cobenfy ARISE and Reblozyl INDEPENDENCE) to ensure that probability of success for future trials is as high as possible; LINK.
Bank of America Securities
$52
Hold
12.43%
Upside
Reiterated
11/03/25
TR | OpenAI - 4o
$47→$50
Hold
8.11%
Upside
Reiterated
10/31/25
AI Generated ArticleAI Generated Article
Bernstein
$58
Hold
25.41%
Upside
Reiterated
10/31/25
Balanced Outlook on Bristol-Myers Squibb: Strong Q3 Performance Amid ADEPT-2 Trial ConcernsWe do highlight that management language has changed from “script inflection once access in place” to “entrenched D2 asset stickiness will cause a steady script trajectory”. The most important factor to support this uptake will be getting “physicians educated and helping them figure out the switching dynamics.” Our take: For the remainder of the year - all eyes are on Cobenfy’s ADEPT-2 read out - this is likely all the matters - if negative, likely down MSD, if positive, potential for a >10% stock move, given current investor pessimism. CEO Boerner seemed confident on the call, and tried to assuage investors concerns. We will also be watching Cobenfy in market performance & changes under new R&D head Massacesi’s leadership (programs, people, strategy).
Cantor Fitzgerald
$45
Hold
-2.70%
Downside
Reiterated
10/31/25
Unknown Analyst
Berenberg BankNot Ranked
Berenberg Bank
$55
Hold
18.92%
Upside
Reiterated
10/24/25
Goldman Sachs
$56→$51
Hold
10.27%
Upside
Reiterated
10/20/25
Bristol-Myers Squibb: Hold Rating Amid Market Challenges and Uncertain Growth ProspectsWe expect a generally in-line set of results (see key variances within) though we expect a 3Q miss for key product (and important sentiment driver) Cobenfy alongside a continued slow launch. Additionally, we expect earnings related metrics could get overshadowed by an unsatisfying update around the ADEPT-2 trial that suggests clinical trial site reviews are still ongoing and timelines for completion remain uncertain. Progress on BNTX partnered PDL1xVEGF bispeci fi c program will matter, though we expect this to also feed into burgeoning investor debates into 2026 about how R&D expenses associated with these programs will impact previously guided cost reductions that management has said would fl ow through the bottom line by the end of 2027.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Hold
―
Reiterated
11/22/25
Truist Financial
―
Buy
―
Reiterated
11/20/25
Scotiabank
$45
Hold
-2.70%
Downside
Reiterated
11/20/25
BMO Capital
$47
Hold
1.62%
Upside
Reiterated
11/18/25
Citi
$48→$45
Hold
-2.70%
Downside
Reiterated
11/17/25
Piper Sandler
$62
Buy
34.05%
Upside
Reiterated
11/17/25
Morgan Stanley
$36
Sell
-22.16%
Downside
Reiterated
11/14/25
Bristol-Myers Squibb Faces Setbacks with Milvexian Trials, Justifying Sell RatingWe view this as another setback for the Factor XI thesis following the announcement in Nov. '23 that Bayer (covered by Thibault Boutherin) stopped the Ph3 OCEANIC-AF trial of asundexian (Factor XI) vs. Eliquis in afib early due to lack of efficacy; LINK. We previously highlighted that we viewed this news as an incremental negative for Milvexian as it could be reflective of the high bar set by Eliquis in afib and imply a lower probability of success for Milvexian in afib (LINK, LINK). As a reminder, BMY previously announced it was conducting clinical trial site reviews across all of its ongoing clinical trials in light of recent trial failures (Camzyos ODYSSEY-HCM, Cobenfy ARISE and Reblozyl INDEPENDENCE) to ensure that probability of success for future trials is as high as possible; LINK.
Bank of America Securities
$52
Hold
12.43%
Upside
Reiterated
11/03/25
TR | OpenAI - 4o
$47→$50
Hold
8.11%
Upside
Reiterated
10/31/25
AI Generated ArticleAI Generated Article
Bernstein
$58
Hold
25.41%
Upside
Reiterated
10/31/25
Balanced Outlook on Bristol-Myers Squibb: Strong Q3 Performance Amid ADEPT-2 Trial ConcernsWe do highlight that management language has changed from “script inflection once access in place” to “entrenched D2 asset stickiness will cause a steady script trajectory”. The most important factor to support this uptake will be getting “physicians educated and helping them figure out the switching dynamics.” Our take: For the remainder of the year - all eyes are on Cobenfy’s ADEPT-2 read out - this is likely all the matters - if negative, likely down MSD, if positive, potential for a >10% stock move, given current investor pessimism. CEO Boerner seemed confident on the call, and tried to assuage investors concerns. We will also be watching Cobenfy in market performance & changes under new R&D head Massacesi’s leadership (programs, people, strategy).
Cantor Fitzgerald
$45
Hold
-2.70%
Downside
Reiterated
10/31/25
Unknown Analyst
Berenberg BankNot Ranked
Berenberg Bank
$55
Hold
18.92%
Upside
Reiterated
10/24/25
Goldman Sachs
$56→$51
Hold
10.27%
Upside
Reiterated
10/20/25
Bristol-Myers Squibb: Hold Rating Amid Market Challenges and Uncertain Growth ProspectsWe expect a generally in-line set of results (see key variances within) though we expect a 3Q miss for key product (and important sentiment driver) Cobenfy alongside a continued slow launch. Additionally, we expect earnings related metrics could get overshadowed by an unsatisfying update around the ADEPT-2 trial that suggests clinical trial site reviews are still ongoing and timelines for completion remain uncertain. Progress on BNTX partnered PDL1xVEGF bispeci fi c program will matter, though we expect this to also feed into burgeoning investor debates into 2026 about how R&D expenses associated with these programs will impact previously guided cost reductions that management has said would fl ow through the bottom line by the end of 2027.
Best Analysts Covering Bristol-Myers Squibb
1 Month
xxx
Success Rate
10/19 ratings generated profit
Average Return
-1.67%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 52.63% of your transactions generating a profit, with an average return of -1.67% per trade.
3 Months
xxx
Success Rate
17/27 ratings generated profit
Average Return
+2.20%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.96% of your transactions generating a profit, with an average return of +2.20% per trade.
1 Year
Success Rate
22/27 ratings generated profit
Average Return
+8.11%
reiterated a sell rating 10 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 81.48% of your transactions generating a profit, with an average return of +8.11% per trade.
2 Years
xxx
Success Rate
22/27 ratings generated profit
Average Return
+11.72%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 81.48% of your transactions generating a profit, with an average return of +11.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BMY Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
1
1
0
0
0
Buy
14
19
18
14
14
Hold
40
42
36
33
30
Sell
3
3
4
2
3
Strong Sell
0
0
0
0
0
total
58
65
58
49
47
Each month's total comprises the sum of three months' worth of ratings.
BMY Financial Forecast
BMY Stock Forecast FAQ
What is BMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 52.67.
What is BMY’s upside potential, based on the analysts’ average price target?
Bristol-Myers Squibb has 13.88% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BMY a Buy, Sell or Hold?
Bristol-Myers Squibb has a consensus rating of Moderate Buy which is based on 6 buy ratings, 11 hold ratings and 1 sell ratings.
What is Bristol-Myers Squibb’s price target?
The average price target for Bristol-Myers Squibb is 52.67. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $68.00 ,the lowest forecast is $36.00. The average price target represents 13.88% Increase from the current price of $46.25.
The highest analyst price target is $68.00 ,the lowest forecast is $36.00. The average price target represents 13.88% Increase from the current price of $46.25.
What do analysts say about Bristol-Myers Squibb?
Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of BMY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.